Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.
AB Sciex

New Genetic Test for Breast Cancer Launched

By Labmedica International staff writers
Posted on 17 Dec 2013
Image: BRCAvantage collection kit (Photo courtesy of Quest Diagnostics).
Image: BRCAvantage collection kit (Photo courtesy of Quest Diagnostics).
A cutting-edge test that identifies mutations in breast cancer genes (BRCA1 and BRCA2) that are associated with increased risk of inherited breast and ovarian cancers has been launched.

A woman with a confirmed BRCA1 or BRCA2 gene mutations is at greater risk of developing cancer during her lifetime with up to an 85% risk of breast cancer and up to a 40% risk of ovarian cancer compared to the general population.

The assay is called BRCAvantage and comprises four individual tests that are administered on the basis of a patient’s risk level. The test screens for known harmful BRCA 1/2 mutations using next generation sequencing and multiplex ligation-dependent probe amplification (MLPA). Identified gene variants are cross-referenced with mutational databases for clinical analysis. To facilitate the implementation of BRCAvantage, the production company, Quest Diagnostics (Madison, NJ, USA), announced that it will offer clinicians and patients access to third-party genetic counselors.

BRCA1 and BRCA2 are genes with known mutations responsible for increasing the risk of hereditary breast and ovarian cancer and associated cancers in women, and for prostate and breast cancer among men. Genetic testing is recommended for people with an immediate family member diagnosed with breast cancer at age 45 or younger; a personal history of breast cancer at age 45 or younger; a family member diagnosed with ovarian cancer at any age; a personal or family history of both breast and ovarian cancers on the same side of the family; a personal or family history of male breast cancer; Ashkenazi Jewish heritage, or a personal or family history of bilateral breast cancer.

Jon R. Cohen, MD, senior vice president and chief medical officer at Quest diagnostics said, “Quest stands for the power of knowing. Making sure patients have access to a genetic test with proven clinical value is essential. Patients need to understand their cancer risks in order to make the most informed and timeliest decisions about their health. While not every woman should get a BRCA test, Quest has a special opportunity to ensure every woman for whom BRCA testing is indicated can access this important technology.”

Related Links:

Quest Diagnostics



PURITAN MEDICAL
ADVANCED INSTRUMENTS
GREINER-BIO-ONE
BioConferenceLive

Channels

Clinical Chemistry

view channel

Five-Minute Kit-on-a-Lid Assay Detects Asthma from Whole Blood

A team of bioengineers has developed a simple, hand-held device that enables diagnosis of asthma from a single drop of blood. The "kit-on-a-lid-assay (KOALA)" microfluidic technology used to perform the test is the brain child of investigators at the University of Wisconsin (Madison, USA). KOALA capitalizes on differences... Read more

Hematology

view channel

Blood Donations Screened for Viruses Using Multiplex Assay

A global healthcare company was chosen to partner the Japanese Red Cross (JRC; Tokyo, Japan) for nucleic acid screening of the nation's blood supply. Under the terms of the 7-year agreement, the healthcare company, Grifols (Barcelona, Spain) will provide the JRC with its newest automation platform, the Procleix Panther... Read more

Pathology

view channel
Image: The Infinium HumanMethylation27 BeadChip Kit uses the Infinium Methylation Assay and is compatible with the iScan, HiScan, and Bead Array Reader systems (Photo courtesy of Illumina).

Methylated DNA Blood Test Monitors Breast Cancer Progress and Treatment Response

An advanced assay that measures DNA hypermethylatation in blood samples can diagnose advanced breast cancer, as well as monitor tumor burden and treatment response in women with metastatic breast tumors.... Read more

Industry News

view channel

Bio-Rad Acquires GnuBIO and Fast Integrated DNA Sequencing Platform

Global life science and clinical diagnostics company Bio-Rad Laboratories, Inc. (Hercules, CA, USA) has purchased GnuBIO, Inc. (Cambridge, MA. USA), a privately-held company that has developed a novel droplet-based DNA sequencing technology and a system that incorporates all DNA sequencing functions into a single, integrated... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.